Alder Biopharma (Bothell, WA) developer of unique antibody technologies that may increase antibody potency, accelerate production cycles, and lower production costs closed a $40M Series C financing. Participants include Delphi Ventures, TPG Biotech, Sevin Rosen Funds, Ventures West, H.I.G. Ventures, and WRF Capital.